Effect of NSAID Consumption on Renal Cell Carcinoma Prognosis: A Population-Based Study

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-02-08 DOI:10.1016/j.clgc.2025.102311

Ilkka Kemppinen, Antti Pöyhönen, Priit Veskimäe, Thea Veitonmäki, Teuvo Tammela, Teemu J. Murtola

{"title":"Effect of NSAID Consumption on Renal Cell Carcinoma Prognosis: A Population-Based Study","authors":"Ilkka Kemppinen, Antti Pöyhönen, Priit Veskimäe, Thea Veitonmäki, Teuvo Tammela, Teemu J. Murtola","doi":"10.1016/j.clgc.2025.102311","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The objective is to study the effect of NSAID consumption on renal cell carcinoma prognosis.</div></div><div><h3>Methods</h3><div>In retrospective cohort study patients diagnosed with renal cell carcinoma (RCC) between 1995 and 2015 (<em>n</em> = 7492) were divided into subgroups based on their NSAID use. Multivariate adjusted analyses were performed using cox's regression model to evaluate hazard ratio for RCC mortality. Analyses were conducted separately for acetylsalicylic acid (ASA), COX-2 selective inhibitor (COXIB), and NSAID (including ASA and COXIB) users.</div></div><div><h3>Results</h3><div>Any NSAID consumption prior to the diagnosis of RCC exhibits a slightly elevated mortality rate compared to individuals who do not consume NSAIDs (HR 1.08, 95% CI 1.00-1.16). Pre- and postdiagnostic ASA and KOKSIB use, as well as postdiagnostic NSAID, ASA, and COXIB use, weren't associated with RCC mortality. Among women, NSAID use elevated RCC mortality both prior to the diagnosis (HR 1.21, 95% CI 1.08-1.36, <em>P</em> = .005) and after the diagnosis (HR 1.15, 95% CI 1.05-1.29, <em>P</em> = .046).</div></div><div><h3>Conclusion</h3><div>Prediagnostic NSAID consumption slightly elevated RCC mortality. Among women, both pre- and postdiagnostic NSAID use is associated with heightened RCC mortality.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102311"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000138","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective is to study the effect of NSAID consumption on renal cell carcinoma prognosis.

Methods

In retrospective cohort study patients diagnosed with renal cell carcinoma (RCC) between 1995 and 2015 (n = 7492) were divided into subgroups based on their NSAID use. Multivariate adjusted analyses were performed using cox's regression model to evaluate hazard ratio for RCC mortality. Analyses were conducted separately for acetylsalicylic acid (ASA), COX-2 selective inhibitor (COXIB), and NSAID (including ASA and COXIB) users.

Results

Any NSAID consumption prior to the diagnosis of RCC exhibits a slightly elevated mortality rate compared to individuals who do not consume NSAIDs (HR 1.08, 95% CI 1.00-1.16). Pre- and postdiagnostic ASA and KOKSIB use, as well as postdiagnostic NSAID, ASA, and COXIB use, weren't associated with RCC mortality. Among women, NSAID use elevated RCC mortality both prior to the diagnosis (HR 1.21, 95% CI 1.08-1.36, P = .005) and after the diagnosis (HR 1.15, 95% CI 1.05-1.29, P = .046).

Conclusion

Prediagnostic NSAID consumption slightly elevated RCC mortality. Among women, both pre- and postdiagnostic NSAID use is associated with heightened RCC mortality.

查看原文本刊更多论文

非甾体抗炎药对肾细胞癌预后的影响：一项基于人群的研究

目的探讨非甾体抗炎药对肾细胞癌预后的影响。方法回顾性队列研究1995 - 2015年诊断为肾细胞癌（RCC）的患者（n = 7492），根据其使用非甾体抗炎药的情况分为亚组。采用cox回归模型进行多因素校正分析，评价RCC死亡率的风险比。分别对乙酰水杨酸（ASA）、COX-2选择性抑制剂（COXIB）和非甾体抗炎药（包括ASA和COXIB）使用者进行分析。结果与未服用非甾体抗炎药的患者相比，在诊断为RCC之前服用非甾体抗炎药的患者死亡率略高（HR 1.08, 95% CI 1.00-1.16）。诊断前和诊断后ASA和KOKSIB的使用，以及诊断后NSAID、ASA和COXIB的使用与RCC死亡率无关。在女性中，非甾体抗炎药在诊断前（HR 1.21, 95% CI 1.08-1.36, P = 0.005）和诊断后（HR 1.15, 95% CI 1.05-1.29, P = 0.046）均升高了RCC死亡率。结论诊断前服用非甾体抗炎药可轻微提高RCC死亡率。在女性中，诊断前和诊断后使用非甾体抗炎药均与RCC死亡率升高相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.